Permanent hearing loss affects more than 5% of the world's population, yet there are no
nondevice therapies that can protect or restore hearing. Delivery of therapeutics to the …

Hearing impairment is the most frequent sensory deficit in humans of all age groups, from
children (1/500) to the elderly (more than 50% of the over-75 s). Over 50% of congenital …

Mice lacking the vesicular glutamate transporter-3 (VGLUT3) are congenitally deaf due to
loss of glutamate release at the inner hair cell afferent synapse. Cochlear delivery of …

Sensorineural hearing loss (SNHL) is the most common sensory disorder. Its underlying
etiologies include a broad spectrum of genetic and environmental factors that can lead to …

Inner ear gene therapy using adeno-associated viral vectors (AAV) promises to alleviate
hearing and balance disorders. We previously established the benefits of Anc80L65 in …

Gene therapy, or the treatment of human disease using genetic material, for inner ear
dysfunction is coming of age. Recent progress in developing gene therapy treatments for …

Hair cells are sensory receptors for the auditory and vestibular system in vertebrates. The
transcription factor Atoh1 is both necessary and sufficient for the differentiation of hair cells …

Usher syndrome (USH) is a major cause of deaf-blindness in humans, affecting∼ 400 000
patients worldwide. Three clinical subtypes, USH1-3, have been defined, with 10 USH …

Hearing loss is the most common sensory impairment in humans and currently disables 466
million people across the world. Congenital deafness affects at least 1 in 500 newborns, and …

Hearing loss, including genetic hearing loss, is one of the most common forms of sensory
deficits in humans with limited options of treatment. Adeno-associated virus (AAV)-mediated …